Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants
- PMID: 3332796
Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants
Abstract
Bronchiolitis is one of the most serious pulmonary infections commonly caused by respiratory syncytial virus (RSV). RSV disease occurs in yearly epidemics and is most severe in children 1 year of age or younger. Approximately 1 in 50 to 1 in 100 infants are hospitalized after their first infection, and mortality fluctuates between 0.5 and 5.0 per cent. Patients with underlying conditions such as congenital heart disease and bronchopulmonary dysplasia are at higher risk for morbidity and mortality. Methods for rapid diagnosis of RSV infection and the advent of specific therapy with aerosolized ribavirin have revolutionized the management of hospitalized patients with moderate to severe disease. A 3- to 5-day course of ribavirin plus supportive measures should be used in infants who prove to be infected by RSV and who are deteriorating on traditional supportive therapy, and/or who have underlying cardiac and/or pulmonary or immune defects.
Similar articles
-
Refractory congestive heart failure after ribavirin in infants with heart disease and respiratory syncytial virus.Nebr Med J. 1990 Feb;75(2):23-6. Nebr Med J. 1990. PMID: 2308658
-
A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection.N Engl J Med. 1991 Jul 4;325(1):24-9. doi: 10.1056/NEJM199107043250105. N Engl J Med. 1991. PMID: 1904551 Clinical Trial.
-
Pathogenesis and treatment of bronchiolitis.Clin Pharm. 1993 Feb;12(2):95-116. Clin Pharm. 1993. PMID: 8095871 Review.
-
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.N Engl J Med. 1983 Jun 16;308(24):1443-7. doi: 10.1056/NEJM198306163082403. N Engl J Med. 1983. PMID: 6343860 Clinical Trial.
-
Clinical review of ribavirin.Infect Control. 1987 May;8(5):215-8. doi: 10.1017/s0195941700065978. Infect Control. 1987. PMID: 3298116 Review.
Cited by
-
The application and mechanism of action of ribavirin in therapy of hepatitis C.Antivir Chem Chemother. 2012 Sep 25;23(1):1-12. doi: 10.3851/IMP2125. Antivir Chem Chemother. 2012. PMID: 22592135 Free PMC article. Review.
-
Lassa Virus Treatment Options.Microorganisms. 2021 Apr 7;9(4):772. doi: 10.3390/microorganisms9040772. Microorganisms. 2021. PMID: 33917071 Free PMC article. Review.
-
Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.Immunology. 2014 Sep;143(1):1-12. doi: 10.1111/imm.12313. Immunology. 2014. PMID: 24801878 Free PMC article. Review.
-
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.Pharmacoeconomics. 2007;25(1):55-71. doi: 10.2165/00019053-200725010-00006. Pharmacoeconomics. 2007. PMID: 17192118
-
Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection.Lung. 1990;168 Suppl:422-9. doi: 10.1007/BF02718160. Lung. 1990. PMID: 2117144 Review.